Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 123

1.

Amount, Source, and Quality of Support as Predictors of Women's Birth Evaluations.

Simon RM, Johnson KM, Liddell J.

Birth. 2016 Mar 17. doi: 10.1111/birt.12227. [Epub ahead of print]

PMID:
26991407
2.

Does Prostate Size Predict the Development of Incident Lower Urinary Tract Symptoms in Men with Mild to No Current Symptoms? Results from the REDUCE Trial.

Simon RM, Howard LE, Moreira DM, Roehrborn C, Vidal AC, Castro-Santamaria R, Freedland SJ.

Eur Urol. 2015 Dec 24. pii: S0302-2838(15)01210-5. doi: 10.1016/j.eururo.2015.12.002. [Epub ahead of print]

PMID:
26724841
3.

Effect of utilization of veno-venous bypass vs. cardiopulmonary bypass on complications for high level inferior vena cava tumor thrombectomy and concomitant radical nephrectomy.

Simon RM, Kim T, Espiritu P, Kurian T, Sexton WJ, Pow-Sang JM, Sverrisson E, Spiess PE.

Int Braz J Urol. 2015 Sep-Oct;41(5):911-9. doi: 10.1590/S1677-5538.IBJU.2014.0371.

4.

Analytical Validation and Application of a Targeted Next-Generation Sequencing Mutation-Detection Assay for Use in Treatment Assignment in the NCI-MPACT Trial.

Lih CJ, Sims DJ, Harrington RD, Polley EC, Zhao Y, Mehaffey MG, Forbes TD, Das B, Walsh WD, Datta V, Harper KN, Bouk CH, Rubinstein LV, Simon RM, Conley BA, Chen AP, Kummar S, Doroshow JH, Williams PM.

J Mol Diagn. 2016 Jan;18(1):51-67. doi: 10.1016/j.jmoldx.2015.07.006. Epub 2015 Nov 18.

PMID:
26602013
5.

Do all men with pathological Gleason score 8-10 prostate cancer have poor outcomes? Results from the SEARCH database.

Fischer S, Lin D, Simon RM, Howard LE, Aronson WJ, Terris MK, Kane CJ, Amling CL, Cooperberg MR, Freedland SJ, Vidal AC.

BJU Int. 2015 Sep 9. doi: 10.1111/bju.13319. [Epub ahead of print]

PMID:
26351095
6.

Adverse pathology and undetectable ultrasensitive prostate-specific antigen after radical prostatectomy: is adjuvant radiation warranted?

Simon RM, Howard LE, Freedland SJ, Aronson WJ, Terris MK, Kane CJ, Amling CL, Cooperberg MR, Vidal AC.

BJU Int. 2015 May 24. doi: 10.1111/bju.13182. [Epub ahead of print]

PMID:
26010251
7.

GeneMed: An Informatics Hub for the Coordination of Next-Generation Sequencing Studies that Support Precision Oncology Clinical Trials.

Zhao Y, Polley EC, Li MC, Lih CJ, Palmisano A, Sims DJ, Rubinstein LV, Conley BA, Chen AP, Williams PM, Kummar S, Doroshow JH, Simon RM.

Cancer Inform. 2015 Mar 19;14(Suppl 2):45-55. doi: 10.4137/CIN.S17282. eCollection 2015. Review.

8.

The association of exercise with both erectile and sexual function in black and white men.

Simon RM, Howard L, Zapata D, Frank J, Freedland SJ, Vidal AC.

J Sex Med. 2015 May;12(5):1202-10. doi: 10.1111/jsm.12869. Epub 2015 Mar 20.

PMID:
25801073
9.

Use of serial multiparametric magnetic resonance imaging in the management of patients with prostate cancer on active surveillance.

Walton Diaz A, Shakir NA, George AK, Rais-Bahrami S, Turkbey B, Rothwax JT, Stamatakis L, Hong CW, Siddiqui MM, Okoro C, Raskolnikov D, Su D, Shih J, Han H, Parnes HL, Merino MJ, Simon RM, Wood BJ, Choyke PL, Pinto PA.

Urol Oncol. 2015 May;33(5):202.e1-7. doi: 10.1016/j.urolonc.2015.01.023. Epub 2015 Mar 6.

PMID:
25754621
10.

Application of molecular profiling in clinical trials for advanced metastatic cancers.

Kummar S, Williams PM, Lih CJ, Polley EC, Chen AP, Rubinstein LV, Zhao Y, Simon RM, Conley BA, Doroshow JH.

J Natl Cancer Inst. 2015 Feb 6;107(4). pii: djv003. doi: 10.1093/jnci/djv003. Print 2015 Apr.

11.

Clinical implications of a multiparametric magnetic resonance imaging based nomogram applied to prostate cancer active surveillance.

Siddiqui MM, Truong H, Rais-Bahrami S, Stamatakis L, Logan J, Walton-Diaz A, Turkbey B, Choyke PL, Wood BJ, Simon RM, Pinto PA.

J Urol. 2015 Jun;193(6):1943-9. doi: 10.1016/j.juro.2015.01.088. Epub 2015 Jan 26.

PMID:
25633923
12.

Comparison of MR/ultrasound fusion-guided biopsy with ultrasound-guided biopsy for the diagnosis of prostate cancer.

Siddiqui MM, Rais-Bahrami S, Turkbey B, George AK, Rothwax J, Shakir N, Okoro C, Raskolnikov D, Parnes HL, Linehan WM, Merino MJ, Simon RM, Choyke PL, Wood BJ, Pinto PA.

JAMA. 2015 Jan 27;313(4):390-7. doi: 10.1001/jama.2014.17942.

13.

Randomized Trial of Oral Cyclophosphamide and Veliparib in High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers, or BRCA-Mutant Ovarian Cancer.

Kummar S, Oza AM, Fleming GF, Sullivan DM, Gandara DR, Naughton MJ, Villalona-Calero MA, Morgan RJ Jr, Szabo PM, Youn A, Chen AP, Ji J, Allen DE, Lih CJ, Mehaffey MG, Walsh WD, McGregor PM 3rd, Steinberg SM, Williams PM, Kinders RJ, Conley BA, Simon RM, Doroshow JH.

Clin Cancer Res. 2015 Apr 1;21(7):1574-82. doi: 10.1158/1078-0432.CCR-14-2565. Epub 2015 Jan 14.

14.

Radical prostatectomy versus radiation therapy: can pretreatment nomograms be used to select the appropriate prostate cancer treatment?

Simon RM, Salama JK, Freedland SJ.

Eur Urol. 2015 Feb;67(2):210-1. doi: 10.1016/j.eururo.2014.10.009. Epub 2014 Oct 28. No abstract available.

PMID:
25457494
15.

Spinal Cord Injury survey to determine pressure ulcer vulnerability in the outpatient population.

Gould LJ, Olney CM, Nichols JS, Block AR, Simon RM, Guihan M.

Med Hypotheses. 2014 Nov;83(5):552-8. doi: 10.1016/j.mehy.2014.08.027. Epub 2014 Sep 6.

PMID:
25241921
16.

Editorial Comment to Significance of early prostate-specific antigen values after salvage radiotherapy in recurrent prostate cancer patients treated with surgery.

Simon RM, Freedland SJ, Vidal AC.

Int J Urol. 2015 Jan;22(1):88. doi: 10.1111/iju.12621. Epub 2014 Sep 10. No abstract available.

17.

Is the "3+3" dose-escalation phase I clinical trial design suitable for therapeutic cancer vaccine development? A recommendation for alternative design.

Rahma OE, Gammoh E, Simon RM, Khleif SN.

Clin Cancer Res. 2014 Sep 15;20(18):4758-67. doi: 10.1158/1078-0432.CCR-13-2671. Epub 2014 Jul 18.

18.

Diagnostic value of biparametric magnetic resonance imaging (MRI) as an adjunct to prostate-specific antigen (PSA)-based detection of prostate cancer in men without prior biopsies.

Rais-Bahrami S, Siddiqui MM, Vourganti S, Turkbey B, Rastinehad AR, Stamatakis L, Truong H, Walton-Diaz A, Hoang AN, Nix JW, Merino MJ, Wood BJ, Simon RM, Choyke PL, Pinto PA.

BJU Int. 2015 Mar;115(3):381-8. doi: 10.1111/bju.12639. Epub 2014 Sep 15.

19.

Criteria for the use of omics-based predictors in clinical trials: explanation and elaboration.

McShane LM, Cavenagh MM, Lively TG, Eberhard DA, Bigbee WL, Williams PM, Mesirov JP, Polley MY, Kim KY, Tricoli JV, Taylor JM, Shuman DJ, Simon RM, Doroshow JH, Conley BA.

BMC Med. 2013 Oct 17;11:220. doi: 10.1186/1741-7015-11-220.

20.

Criteria for the use of omics-based predictors in clinical trials.

McShane LM, Cavenagh MM, Lively TG, Eberhard DA, Bigbee WL, Williams PM, Mesirov JP, Polley MY, Kim KY, Tricoli JV, Taylor JM, Shuman DJ, Simon RM, Doroshow JH, Conley BA.

Nature. 2013 Oct 17;502(7471):317-20. doi: 10.1038/nature12564.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk